7月2日 - ** Neurizon Therapeutics NUZ.AX股价上涨3.2%至0.160澳元，创6月26日以来最大盘中涨幅。
** 这家生物技术公司与 Elanco Animal Health ELAN.N 签订了全球许可协议， (link)。
** 该协议涉及 Elanco 对 Monepantel 的数据包和相关知识产权的独家使用权，Monepantel 是该公司 NUZ-001 制剂中的活性药物成分，用于神经变性应用。
** 公司股价年初至今下跌 5.9
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.